A new clinical trial suggests that semaglutide — the active ingredient in the widely used drugs Ozempic and Wegovy — may help ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

The average weight for women in the U.S. is 170.8 pounds, and the average height is 5 feet, 3 inches tall. These are mathematical calculations, so they don’t necessarily represent what’s typical or ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

According to the Centers for Disease Control and Prevention, 1 in 7 adults in the United States will experience a substance use disorder during their lifetime. University of Oklahoma College of ...

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

The following is a summary of “A Randomized Clinical Trial of Prolonged Exposure Therapy With and Without Topiramate for Comorbid PTSD and Alcohol Use Disorder,” published in the March 2025 issue of ...